5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase A, individuals will receive various doses and schedules of oral ABBV-744 pill to establish Secure dosing program. More individuals will likely be enrolled in the identified monotherapy dosign routine. In Segment B, participants will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Section C, individuals